Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
336
NCT03300687
First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation
Phase: Early Phase 1
Role: Lead Sponsor
Start: May 30, 2017
Completion: Jan 18, 2018
NCT03616223
FX-322 in Sensorineural Hearing Loss
Phase: Phase 1/2
Start: Jul 3, 2018
Completion: Dec 18, 2018
NCT04120116
FX-322 in Adults With Stable Sensorineural Hearing Loss
Phase: Phase 2
Start: Oct 4, 2019
Completion: Dec 17, 2020
NCT04601909
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
Phase: Phase 1
Start: Sep 17, 2020
Completion: May 16, 2022
NCT04629664
FX-322 in Adults With Severe Sensorineural Hearing Loss
Start: Nov 2, 2020
Completion: Sep 20, 2021
NCT05086276
FX-322 in Adults With Acquired Sensorineural Hearing Loss
Start: Oct 12, 2021
Completion: Dec 30, 2022
NCT05664100
First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss
Start: Dec 15, 2022
Completion: Apr 12, 2023